Pharmacokinetic interaction between ritonavir and didanosine when administered concurrently to HIV-infected patients

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 18, Issue 5, 1998, Pages 466-472

  Cato III, Allen ^a,c   Qian, Jiang ^a   Hsu, Ann ^a   Vomvouras, Stephanie ^b   Piergies, Antoni A ^b   Leonard, John ^a   Granneman, Richard ^a  

^a ABBOTT LABORATORIES   (United States)

^b EVANSTON HOSPITAL   (United States)

^c LIGAND PHARMACEUTICALS INC   (United States)

Author keywords

DdI; HIV; Interaction; Pharmacokinetics; Ritonavir

Indexed keywords

DIDANOSINE; RITONAVIR;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG METABOLISM; DRUG MIXTURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS;

EID: 0032529413     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199808150-00008     Document Type: Article

References (36)

1. Kempf DJ, Marsh KC, Denissen JF, et al. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc Natl Acad Sci USA 1995;92: 2484-88.
2. Markowitz M, Saag M, Powderly WG, et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med 1995;333:1534-9.
3. Danner SA, Carr A, Leonard JM, et al. A short-term study of the safety pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N Engl J Med 1995;333:1528-33.
4. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-6.
5. Yarchoan R, Mitsuya H, Myers CE, Broder S. Clinical pharmacology of 3′-azido-2′,3′-dideoxythymidine (zidovudine) and related dideoxynucleosides. N Engl J Med 1989;321:726-38.
6. Shirasaka T, Kavlick MF, Ueno T, et al. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc Natl Acad Sci USA 1995;92:2398-402.
7. Kumar GN, Rodrigues AD, Buko AM, Denissen JF. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther 1996;277:423-31.
8. Ahluwalia G, Johnson MA, Fridland A, et al. Cellular pharmacology of the anti-HIV agent 2′,3′-dideoxyadenosine. Proc Am Acad Cancer Res 1988;29:349.
9. 14C-2′,3′-dideoxyinosine by the in situ perfused rat liver preparation. Biopharm Drug Dispos 1991;12:285-97.
10. Russell JW, Klunk LJ. Comparative pharmacokinetics of new anti-HIV agents: 2′,3′-dideoxyadenosine and 2′,3′-dideoxyinosine. Biochem Pharmacol 1989;38:1385-8.
11. Hartman NR, Yarchoan R, Pluda JM, et al. Pharmacokinetics of 2′,3′-dideoxyadenosine and 2′,3′-dideoxyinosine in patients with severe human immunodeficiency virus infection. Clin Pharmacol Ther 1990;47:647-54.
12. Knupp CA, Shyu WC, Dolin R, et al. Pharmacokinetics of didanosine in patients with acquired immunodeficiency syndrome or acquired immunodeficiency syndrome-related complex. Clin Pharmacol Ther 1991;49:523-35.
13. Marsh KC, Eiden E, McDonald E. Determination of ritonavir, a new HIV protease inhibitor, in biological samples using reversed-phase high-performance liquid chromatography. J Chromatogr 1997;704:307-13.
14. Ritonavir [package insert]. Abbott Park, IL: Abbott Laboratories, 1997.
15. von Moltke LL, Greenblatt DJ, Court MH, Duan SX, Harmatz JS, Shader RI. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants. J Clin Psychopharmacol 1995;15:125-31.
16. Otton SV, Wu D, Joffe RT, Cheung SW, Sellers EM. Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clin Pharmacol Ther 1993;53:401-9.
17. Prozac [package insert]. Indianapolis, IN: Ely Lilly and Company, 1995.
18. Hsu A, Granneman R, Witt G, et al. Multiple dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother 1997;41:654-60.
19. Cato A, Hsu A, Granneman R, et al. Assessment of the pharmacokinetic interaction between the HIV-1 protease inhibitor ABT-538 and fluconazole [abstract 133]. In Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy Conference. Washington, DC: American Society for Microbiology, 1995:211.
20. Cato A, Hsu A, Granneman R, et al. 1995. Assessment of the pharmacokinetic interaction between the HIV-1 protease inhibitor ABT-538 and zidovudine, abstr. 134, p. 211. In Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy Conference. Washington, DC: American Society for Microbiology, 1995:211.
21. Cato A, Bertz R, Cao G, et al. Evaluation of the role of CYP3A inhibition in food and formulation effects on ritonavir absorption. Proceedings of the 7th North American International Society for the Study of Xenobiotics Meeting, 1996:373.
22. Bertz R, Shi H, Cavanaugh J, Hsu A. 1996. Effect of three vehicles, Advera, Ensure, and chocolate milk, on the bioavailability of an oral liquid formulation of ritonavir [abstract A5]. In Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy Conference. Washington, DC: American Society for Microbiology, 1995:5.
23. Knupp CA, Brater DC, Relue J, Barbhaiya RH. Pharmacokinetics of didanosine and ketoconazole after coadministration to patients seropositive for the human immunodeficiency virus. J Clin Pharmacol 1993;33:912-7.
24. Seifert RD, Stewart MB, Sramek JJ, Conrad J, Kaul S, Cutler NR. Pharmacokinetics of co-administered didanosine and stavudine in HIV-seropositive male patients. Br J Clin Pharmacol 1994;38: 405-10.
25. Knupp CA, Graziano FM, Dixon RM, Barbhaiya RH. Pharmacokinetic interaction study of didanosine and ranitidine in patients seropositive for human immunodeficiency virus. Antimicrob Agents Chemother 1992;36:2075-9.
26. May DB, Drew RH, Yedinak KC, Bartlett JA. Effect of simultaneous didanosine administration on itraconazole absorption in healthy volunteers. Pharmacotherapy 1994;14:509-13.
27. Sahai J, Gallicano K, Garber G, Pakuts A, Cameron W. Pharmacokinetics of simultaneously administered zidovudine and didanosine in HIV-seropositive male patients. J Acquir Immune Defic Syndr Hum Retrovirol 1995;10:54-60.
28. Barry M, Howe L, Ormesher S, et al. Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in patients with the acquired immunodeficiency syndrome. Br J Clin Pharmacol 1994;37:421-6.
29. Lambert JS, Seidlin M, Reichman RC, et al. 2′,3′-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. N Engl J Med 1990;322:1333-40.
30. Beskid G, Eskin B, Cleeland R, et al. Antibacterial activity of 2′,3′-deoxyadenosine in vivo and in vitro. Antimicrob Agents Chemother 1981;19:424-8.
31. Shyu WC, Knupp CA, Pittman KA, Dunkle L, Barbhaiya RH. Food-induced reduction in bioavailability of didanosine. Clin Pharmacol Ther 1991;50:503-7.
32. Anderson BD, Wygant MB, Xiang TX, Waugh WA, Stella VJ. Preformulation solubility and kinetic studies of 2′,3′-dideoxypurine nucleosides: potential anti-AIDS agents. Int J Pharm 1988;45:27-37.
33. Knupp CA, Milbrath R, Barbhaiya RH. Effect of time of food administration on the bioavailability of didanosine from a chewable tablet formulation. J Clin Pharmacol 1993;33:568-73.
34. Drusano GL, Yuen GJ, Morse G, et al. Impact of bioavailability on determination of the maximal tolerated dose of 2′,3′-dideoxyinosine in phase I trials. Antimicrob Agents Chemother 1992;36:1280-3.
35. Didanosine [package insert]. Princeton, NJ: Bristol-Myers Squibb Company, 1995.
36. Quellet D, Hsu A, Granneman GR, et al. Assessment of the pharmacokinetic interaction between ritonavir and clarithromycin. Clin Pharmacol Ther 1996;59:144.